Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Although the rapid emergence of coronavirus disease 2019 (COVID-19) poses a considerable threat to global public health, no specific treatment is available for COVID-19. ReDuNing injection (RDN) is a traditional Chinese medicine known to exert antibacterial, antiviral, antipyretic, and anti-inflammatory effects. In addition, RDN has been recommended in the diagnosis and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated pneumonia by the National Health Council and the National Administration of Chinese Medicine. However, there is no information regarding its efficacy against COVID-19.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aim of study</h3><p>This study was designed to determine the clinical efficacy of RDN in patients with COVID-19 and characterize its antiviral activity against SARS-CoV-2 <em>in vitro</em>.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Materials and methods</h3><p>A total of 50 adults with COVID-19 were included in this study, and the primary endpoint was recovery from clinical symptoms following 14 days of treatment. General improvements were defined as the disappearance of the major symptoms of infection including fever, fatigue, and cough. The secondary endpoints included the proportion of patients who achieved clinical symptom amelioration on days 7 and 10, time to clinical recovery, time to a negative nucleic acid test result, duration of hospitalization, and time to defervescence. Plaque reduction and cytopathic effect assays were also performed <em>in vitro</em>, and reverse-transcription quantitative PCR was performed to evaluate the expression of inflammatory cytokines (TNF-α, IP-10, MCP-1, IL-6, IFN-α, IFN-γ, IL-2 and CCL-5) during SARS-CoV-2 infection.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>The RDN group exhibited a shorter median time for the resolution of clinical symptoms (120 vs. 220 h, <em>P</em> < 0.0001), less time to a negative PCR test result (215 vs. 310 h, <em>P</em> = 0.0017), shorter hospitalization (14.8 vs. 18.5 days, <em>P</em> = 0.0002), and lower timeframe for defervescence (24.5 vs. 75 h, <em>P</em> = 0.0001) than the control group. In addition, time to improved imaging was also shorter in the RDN group than in the control group (6 vs.8.9 days, <em>P</em> = 0.0273); symptom resolution rates were higher in the RDN group than in the control group at 7 (96.30% vs. 39.13%, <em>P</em> < 0.0001) and 10 days (96.30% vs. 56.52%, <em>P</em> = 0.0008). No allergic reactions or anaphylactic responses were reported in this trial. RDN markedly inhibited SARS-CoV-2 proliferation and viral plaque formation <em>in vitro</em>. In addition, RDN significantly reduced inflammatory cytokine production in infected cells.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>RDN relieves clinical symptoms in patients with COVID-19 and reduces SARS-CoV-2 infection by regulating inflammatory cytokine-related disorders, suggestion that this medication might be a safe and effective treatment for COVID-19.</p>

Reduning, A Patented Chinese Medicine, Reduces the Susceptibility to H1n1 Influenza of Mice Loaded with Restraint Stress

Epigoitrin, an Alkaloid From Isatis indigotica , Reduces H1N1 Infection in Stress-Induced Susceptible Model in vivo and in vitro .

Protective effect of apple polyphenols against stress-provoked influenza viral infection in restraint mice.

Reduning Plus Ribavirin Display Synergistic Activity Against Severe Pneumonia Induced by H1N1 Influenza A Virus in Mice.

Wanglaoji Herbal Tea Protects Against Influenza-induced Pneumonia in Restraint-Stressed Mice Via Its Anti-inflammatory Effects

Rujin Jiedu decoction protects against influenza virus infection by modulating gut microbiota

Sarcandra Glabraextract Reduces the Susceptibility and Severity of Influenza in Restraint-Stressed Mice

Qingfeiyin Decoction Inhibits H1N1 Virus Infection via Modulation of Gut Microbiota and Inflammatory Pathways in a Murine Model

A New Mechanism of Vitamin C Effects on A/FM/1/47(H1N1) Virus-Induced Pneumonia in Restraint-Stressed Mice

Inhibitory Effects and Related Molecular Mechanisms of Huanglian-Ganjiang Combination Against H1N1 Influenza Virus

Anti-influenza Effect of Essence of Chicken in Mice Loaded with Restraint Stress

A new mechanism of vitamin C effects on A/FM/1/47(H1N1) virus-induced pneumonia in restraint-stressed mice.

Novel insights into stress-induced susceptibility to influenza: corticosterone impacts interferon-β responses by Mfn2-mediated ubiquitin degradation of MAVS

Anti-inflammatory Effects of Reduning Injection on Lipopolysaccharide-Induced Acute Lung Injury of Rats.

Qiangzhi Decoction (c3/4oee Center Dot-Ae +/- Currency Sign) Protects Mice from Influenza A Pneumonia Through Inhibition of Inflammatory Cytokine Storm

Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2

A Study on the Effect of Traditional Chinese medicine Chaihu-guizhi Decoction Reducing the Susceptibility and Severity of Influenza in Depressed Mice

Effect and Mechanism of Reduning Injection on Respiratory Syncytial Virus (RSV)-Induced Airway Inflammation in Mice

New Insights into the Effects and Mechanism of a Classic Traditional Chinese Medicinal Formula on Influenza Prevention.

Ruhao Dashi granules exert therapeutic effects on H1N1 influenza virus infection by altering intestinal microflora composition

Xiaoer Niuhuang Qingxin Powder Alleviates Influenza a Virus Infection by Inhibiting the Activation of the Tlr4/myd88/nfκb Signaling Pathway